|
Safety and Efficacy of Dolutegravir and Maraviroc Plus Background Therapy in HIV-1 Treatment-Experienced Participants
|
|
|
Reported by Jules Levin
22nd Annual Conference of the British HIV Association; April 19-22, 2016; Manchester Central, UK
M Prakash,1 J Huang,2 J Lim,3 J Koteff,4 C Trezza,4 S Griffith,4 M Ait-Khaled,1 B Wynne,5 M Gartland,4 A Clark,1 M Aboud1
1ViiV Healthcare, London, UK; 2GlaxoSmithKline, Mississauga, ON, Canada; 3GlaxoSmithKline, Stockley Park, UK; 4ViiV Healthcare, Research Triangle Park, NC, USA; 5ViiV Healthcare, Collegeville, PA, USA
![HIV1](../images/100816/100816-14/HIV1.gif)
![HIV2](../images/100816/100816-14/HIV2.gif)
![HIV3](../images/100816/100816-14/HIV3.gif)
|
|
|
|
|
|
|